GlassScriptPhysician profile
David Joseph Cho
NPI 1871882076
$3,520.65
in general payments reported to CMS, 2019-2025
21 companies · $550 in 2025
The $550 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $393 · 2021: $518 · 2022: $429 · 2023: $388 · 2024: $580 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354 · Consulting Fee: $145 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,353.77 |
| Consulting Fee | $145.02 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,097.20 | 2019-2023 | Lifevest |
| Boston Scientific Corporation | $548.71 | 2019-2024 | Synergy, Bodyguardian |
| Abiomed | $279.51 | 2019-2025 | Impella |
| Amgen INC. | $274.77 | 2024-2025 | Repatha |
| Abbott Laboratories | $244.53 | 2019-2022 | |
| Cathworks, INC. | $228.42 | 2025 | Ffrangio |
| Novartis Pharmaceuticals Corporation | $135.17 | 2022-2024 | |
| Edwards Lifesciences Corporation | $128.61 | 2019 | |
| Heartflow, INC. | $112.37 | 2023-2025 | Ffrct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.73 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $55.77 | 2023-2025 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $54.29 | 2024 | Arcalyst |
| Philips North America LLC | $50.64 | 2023 | |
| Novo Nordisk INC | $46.35 | 2022-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $45.97 | 2024-2025 | Farxiga |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $30.03 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $27.75 | 2023 | Arcalyst |
| Medtronic, INC. | $23.56 | 2023 | Corevalve Evolut R |
| Regeneron Healthcare Solutions, INC. | $21.73 | 2021 | |
| Glaxosmithkline, LLC. | $19.03 | 2023 | Shingrix |
| Medtronic Vascular, INC. | $18.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.